Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of:
wherein the variables are as defined herein.
Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound of formula:
wherein the variables are as defined herein.
Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors
作者:Michael B. Wallace、Mark E. Adams、Toufike Kanouni、Clifford D. Mol、Douglas R. Dougan、Victoria A. Feher、Shawn M. O’Connell、Lihong Shi、Petro Halkowycz、Qing Dong
DOI:10.1016/j.bmcl.2010.05.058
日期:2010.7
A novel series of pyrrole inhibitors of MEK kinase has been developed using structure-based drug design. Optimization of the series led to the identification of potent inhibitors with good pharmaceutical properties. (C) 2010 Elsevier Ltd. All rights reserved.
US7943659B2
申请人:——
公开号:US7943659B2
公开(公告)日:2011-05-17
[EN] MAPK/ERK KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE MAPK/ERK
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2008055236A2
公开(公告)日:2008-05-08
[EN] Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of ##STR## wherein the variables are as defined herein. [FR] L'invention concerne des composés, compositions pharmaceutique, kits et procédés pour utilisation avec MEK comprenant un composé sélectionné parmi le groupe composé de ##STR##, caractérisés en ce que les variables sont telles que définies dans la présente.